BOSTON, OpenEye miniCUP—Sept. 25, 2025—Cadence Molecular Sciences (OpenEye), a business unit of Cadence (Nasdaq: CDNS), announced today at miniCUP Boston, the launch of ROCS X, an AI-enabled virtual screening solution that allows scientists to conduct 3D searches of trillions of drug-like molecules.
The ROCS X technology was developed and validated through collaboration with Treeline Biosciences, a biotechnology firm focused on addressing serious medical conditions such as cancer. Utilizing ROCS X, Treeline has physically sourced over 150 novel compounds for evaluation as potential drug candidates.
Early access to ROCS X is available now, with general availability expected in the first quarter of 2026. To request advanced access, please contact oe-sales@cadence.com.
Reading the full Cadence ROCS X news release.
For media inquiries, please contact:
Cadence Newsroom
408-944-7039
newsroom@cadence.com
